君实生物(688180)
 
 
  日线
顶尖财经网欢迎您!
  K线
 
 最新动态
  投资评级

研究机构 评级日期 最新评级 上次评级
东北证券 2024-01-30 买入 买入
方正证券 2024-01-14 买入 买入
国金证券 2024-01-03 买入
浙商证券 2023-11-19 买入
天风证券 2023-11-19 买入
光大证券 2023-11-16 买入
  盈利预测
据君实生物三季报分析:

  盈利能力维持稳定,主营获利能力保持稳定

  成长能力有所加强,企业成长潜力得到恢复

  偿债能力维持稳定,即时支付现金能力得到加强

  运营能力维持稳定,资金使用效率有所优化

  现金流能力维持稳定,销售回款能力同步增强

  财务数据
    截至第三季度实现净利润-15.55亿元,每股收益-1.43元。

    截至第三季度最新股东权益833769.87万元,未分配利润-818345.33万元。

    截至第三季度最新总资产1158714.42万元,负债324944.55万元。

利润表
报告期2023-09-302023-06-302023-03-312022-12-31
营业总收入986,457,567.67669,702,667.07255,154,522.241,453,492,709.83
营业总成本2,479,371,840.851,772,814,913.95897,619,704.334,102,931,275.55
营业利润-1,580,362,717.66-1,162,291,985.5-633,218,295.88-2,665,914,431.34
利润总额-1,607,515,370.44-1,176,824,289.32-637,453,868.76-2,677,184,262.29
净利润-1,555,128,891.35-1,126,329,526.49-639,619,944.79-2,584,077,472.69
其他综合收益-50,732,766.43-38,178,177.32-27,447,285.04-68,617,672.36
综合收益总额-1,605,861,657.78-1,164,507,703.81-667,067,229.83-2,652,695,145.05
资产负债表
报告期2023-09-302023-06-302023-03-312022-12-31
流动资产合计5,782,947,053.416,423,505,057.986,791,366,233.027,216,484,067
非流动资产合计5,804,197,167.985,355,971,828.975,339,562,243.285,342,012,108.43
资产总计11,587,144,221.3911,779,476,886.9512,130,928,476.312,558,496,175.43
流动负债合计1,849,722,788.781,838,841,490.221,757,007,064.851,766,310,611.88
非流动负债合计1,399,722,758.661,155,125,700.21,099,543,899.251,015,725,300.33
负债合计3,249,445,547.442,993,967,190.422,856,550,964.12,782,035,912.21
归属于母公司股东权益合计8,064,611,883.598,493,075,006.928,949,235,488.329,483,626,151.7
股东权益合计8,337,698,673.958,785,509,696.539,274,377,512.29,776,460,263.22
负债和股东权益合计11,587,144,221.3911,779,476,886.9512,130,928,476.312,558,496,175.43
现金流量表
报告期2023-09-302023-06-302023-03-312022-12-31
经营活动现金流入小计1,236,480,347.79724,254,775.41302,002,091.082,739,654,759.49
经营活动现金流出小计2,900,594,540.441,949,976,576.481,022,253,055.974,515,855,672.59
经营活动产生的现金流量净额-1,664,114,192.65-1,225,721,801.07-720,250,964.89-1,776,200,913.1
投资活动现金流入小计1,290,836,234.041,265,278,847432,767,530.31152,223,319.65
投资活动现金流出小计1,944,670,480.181,431,430,071.66925,640,355.94589,435,844.85
投资活动产生的现金流量净额-653,834,246.14-166,151,224.66-492,872,825.63-437,212,525.2
筹资活动现金流入小计937,789,838.5411,620,629.53248,567,750.195,024,283,327.67
筹资活动现金流出小计496,595,535.82188,022,407.3737,114,589.49410,805,199.67
筹资活动产生的现金流量净额441,194,302.68223,598,222.16211,453,160.74,613,478,128
汇率变动对现金及现金等价物的影响21,536,381.0525,100,592.95-10,637,565.2992,266,469.41
现金及现金等价物净增加额-1,855,217,755.06-1,143,174,210.62-1,012,308,195.112,492,331,159.11
期末现金及现金等价物余额4,141,718,242.774,853,761,787.214,984,627,802.725,996,935,997.83
  主营收入+营业利润
 
  净利润+每股收益
  股东权益+未分配利润
 
  总资产+负债
  投资要点

    截至第三季度实现净利润-15.55亿元,每股收益-1.43元。

    截至第三季度最新股东权益833769.87万元,未分配利润-818345.33万元。

    截至第三季度最新总资产1158714.42万元,负债324944.55万元。

利润表
报告期2023-09-302023-06-302023-03-312022-12-31
营业总收入986,457,567.67669,702,667.07255,154,522.241,453,492,709.83
营业总成本2,479,371,840.851,772,814,913.95897,619,704.334,102,931,275.55
营业利润-1,580,362,717.66-1,162,291,985.5-633,218,295.88-2,665,914,431.34
利润总额-1,607,515,370.44-1,176,824,289.32-637,453,868.76-2,677,184,262.29
净利润-1,555,128,891.35-1,126,329,526.49-639,619,944.79-2,584,077,472.69
其他综合收益-50,732,766.43-38,178,177.32-27,447,285.04-68,617,672.36
综合收益总额-1,605,861,657.78-1,164,507,703.81-667,067,229.83-2,652,695,145.05
资产负债表
报告期2023-09-302023-06-302023-03-312022-12-31
流动资产合计5,782,947,053.416,423,505,057.986,791,366,233.027,216,484,067
非流动资产合计5,804,197,167.985,355,971,828.975,339,562,243.285,342,012,108.43
资产总计11,587,144,221.3911,779,476,886.9512,130,928,476.312,558,496,175.43
流动负债合计1,849,722,788.781,838,841,490.221,757,007,064.851,766,310,611.88
非流动负债合计1,399,722,758.661,155,125,700.21,099,543,899.251,015,725,300.33
负债合计3,249,445,547.442,993,967,190.422,856,550,964.12,782,035,912.21
归属于母公司股东权益合计8,064,611,883.598,493,075,006.928,949,235,488.329,483,626,151.7
股东权益合计8,337,698,673.958,785,509,696.539,274,377,512.29,776,460,263.22
负债和股东权益合计11,587,144,221.3911,779,476,886.9512,130,928,476.312,558,496,175.43
现金流量表
报告期2023-09-302023-06-302023-03-312022-12-31
经营活动现金流入小计1,236,480,347.79724,254,775.41302,002,091.082,739,654,759.49
经营活动现金流出小计2,900,594,540.441,949,976,576.481,022,253,055.974,515,855,672.59
经营活动产生的现金流量净额-1,664,114,192.65-1,225,721,801.07-720,250,964.89-1,776,200,913.1
投资活动现金流入小计1,290,836,234.041,265,278,847432,767,530.31152,223,319.65
投资活动现金流出小计1,944,670,480.181,431,430,071.66925,640,355.94589,435,844.85
投资活动产生的现金流量净额-653,834,246.14-166,151,224.66-492,872,825.63-437,212,525.2
筹资活动现金流入小计937,789,838.5411,620,629.53248,567,750.195,024,283,327.67
筹资活动现金流出小计496,595,535.82188,022,407.3737,114,589.49410,805,199.67
筹资活动产生的现金流量净额441,194,302.68223,598,222.16211,453,160.74,613,478,128
汇率变动对现金及现金等价物的影响21,536,381.0525,100,592.95-10,637,565.2992,266,469.41
现金及现金等价物净增加额-1,855,217,755.06-1,143,174,210.62-1,012,308,195.112,492,331,159.11
期末现金及现金等价物余额4,141,718,242.774,853,761,787.214,984,627,802.725,996,935,997.83
  十大流通股东
十大流通股东 报告期:2023-09-30
股东名称 持股数量(万股) 占总股本比例(%) 上期持股变化(万股)
香港中央结算(代理人)有限公司21929.1230.380.00
上海檀英投资合伙企业(有限合伙)7659.0010.610.00
招商银行股份有限公司-华夏上证科创板50成份交易型开放式指数证券投资基金3809.815.281331.27
香港中央结算有限公司1354.411.88143.72
中国工商银行股份有限公司-易方达上证科创板50成份交易型开放式指数证券投资基金1226.921.70408.13
王振花1101.021.530.00
黄菲1058.391.47-21.34
石雯894.751.240.00
中国银行股份有限公司-招商国证生物医药指数分级证券投资基金830.281.154.07
张俊684.050.950.00
  主力控盘
  公司简介
君实生物 所属地域: -- 涉及概念: 猴痘概念,新冠特效药,创新药,沪股通,生物医药,融资融券
主营业务: 生物医药的研发,并提供相关的技术开发、技术咨询、技术转让、技术服务,从事货物及技术的进出口业务。药品批发,药品委托生产。(详见药品上市许可持有人药品注册批件)【依法须经批准的项目,经相关部门批准后方可开展经营活动】
上市日期: 2020-07-15 每股净资产: 8.18元 每股收益: -1.43元 净利润: -14.07亿元 净利润增长率: 11.78%
营业收入: 9.86亿元 每股现金流: -1.69元 每股公积金: 15.62元 每股未分配利润: -8.30元 总股本: 9.86亿 流通股: 6.82亿
以上信息为合作方、加盟公司及会员收集,本站不拥有版权,版权归原作者所有,所载文章、数据仅供参考,据此操作,风险自负。

中 华 顶 尖 财 经 -- 中 华 顶 尖 网 络 信 息 服 务 中 心